Evaluation of Topical Povidone-Iodine in Chronic Suppurative Otitis Media | Otolaryngology | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Youngs  R Chronic suppurative otitis media—mucosal disease.  In: Ludman  H, Wright  T, eds.  Diseases of the Ear. 6th ed. London, England: Edward Arnold Publishers Ltd; 1998:374-385. Google Scholar
2.
Jokipii  AMKarma  POjala  KJokipii  L Anaerobic bacteria in chronic otitis media.  Arch Otolaryngol.1977;103:278-280.PubMedGoogle Scholar
3.
Rohn  GNMeyerhoff  WLWright  CG Ototoxicity of topical agents.  Otolaryngol Clin North Am.1993;26:747-758.PubMedGoogle Scholar
4.
Fradis  MBrodsky  ABen-David  JSrugo  ILarboni  JPodoshin  L Chronic otitis media treated topically with ciprofloxacin or tobramycin.  Arch Otolaryngol Head Neck Surg.1997;123:1057-1060.PubMedGoogle Scholar
5.
Tutkun  AOzagar  AKoc  ABatman  CUneri  CSehitoglu  MA Treatment of chronic ear disease, topical ciprofloxacin vs topical gentamicin.  Arch Otolaryngol Head Neck Surg.1995;121:1414-1416.PubMedGoogle Scholar
6.
Paton  JHReeves  DS Fluoroquinolone antibiotics: microbiology, pharmacokinetics and clinical use.  Drugs.1988;36:193-228.PubMedGoogle Scholar
7.
Fleischer  WReimer  K Povidone-iodine in antisepsis-state of the art.  Dermatology.1997;195(suppl 2):3-9.PubMedGoogle Scholar
8.
Kunisada  TYamada  KOda  SHara  O Investigation of efficacy of PVP-I against antiseptic resistant species.  Dermatology.1997;195(suppl 2):14-18.PubMedGoogle Scholar
9.
Perez  RFreeman  SSohmer  HSichel  JY Vestibular and cochlear ototoxicity of topical antiseptics assessed by evoked potentials.  Laryngoscope.2000;110:1522-1527.PubMedGoogle Scholar
10.
Aursnes  J Ototoxic effect of iodine disinfectants.  Acta Otolaryngol.1982;93:219-226.PubMedGoogle Scholar
11.
Chevretton  EBMcRae  RDBooth  JB Mastoidectomy packs: xeroform or BIPPS [letter]?  J Laryngol Otol.1992;106:387-388.PubMedGoogle Scholar
12.
Not Available Performance Standards for Antimicrobial Disc Susceptibility Tests: Approved Standard—Seventh Edition.  Wayne, Pa: National Committee for Clinical Laboratory Standards; 2000. NCCLS document M2-A7.
13.
Yasuda  TYoshimura  YTakada  H  et al Comparison of bactericidal effects of commonly used antiseptics against pathogens causing nosocomial infections.  Dermatology.1997;195(suppl 2):19-28.PubMedGoogle Scholar
14.
Canalis  RFLambert  PR Chronic otitis media and cholesteatoma.  In: Canalis  RF, Lambert  PR, eds.  The Ear, Comprehensive Otology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:409-431. Google Scholar
15.
Mentonga  D The topical use of gentamicin in otorrhoea.  Practitioner.1969;203:786-788.PubMedGoogle Scholar
Original Article
October 2003

Evaluation of Topical Povidone-Iodine in Chronic Suppurative Otitis Media

Author Affiliations

From the Departments of Otorhinolaryngology and Head and Neck Surgery (Drs Jaya and Job), Clinical Microbiology (Dr Mathai), and Biostatistics (Dr Antonisamy), Christian Medical College, Vellore, India. The authors have no relevant financial interest in this article.

Arch Otolaryngol Head Neck Surg. 2003;129(10):1098-1100. doi:10.1001/archotol.129.10.1098
Abstract

Objectives  To evaluate if povidone-iodine (PVP-I) can be used topically in the treatment of chronic suppurative otitis media–tubotympanic disease and to compare it with ciprofloxacin hydrochloride ear drops.

Design  Prospective double-blind randomized study.

Setting  Academic tertiary medical center.

Patients  Forty patients with chronic suppurative otitis media were randomized into 2 groups.

Intervention  One group (19 patients) received 5% PVP-I ear drops, while the other group (21 patients) received 0.3% ciprofloxacin ear drops. Both were administered topically, 3 drops 3 times daily for 10 days. These patients were followed up at weekly intervals for up to 4 weeks after commencing therapy.

Results  Clinical improvement at the end of study was 88% in the PVP-I group and 90% in the ciprofloxacin group. The most commonly isolated organism was Pseudomonas aeruginosa. In vitro resistance to ciprofloxacin was seen in 17% of organisms, while no resistance was seen for PVP-I.

Conclusions  To our knowledge, this is the first study to evaluate the efficacy of PVP-I as a topical agent in the treatment of chronic suppurative otitis media. The results show that clinically, topical PVP-I is as effective as topical ciprofloxacin, with a superior advantage of having no in vitro drug resistance. Also, there is an added benefit of reduced cost of therapy.

×